Clinical Study
Ultrasound Guided Core Biopsy versus Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients with Breast Cancer
Table 2
Sensitivity of core biopsy versus FNA for detection of 70 patients with Axillary node metastases.
| Factor | | Core detected (%) | FNA detected (%) | Difference in sensitivities (core-FNA) |
Discordant | value |
| Overall | 70 | 61 (87.1) | 55 (78.6) | 8.6% | 14 | 0.18 | Number of core passes | | | | | | | 1 pass | 14 | 11 (78.6) | | | | | >1 | 56 | 50 (89.3) | | | | | Core needle size | | | | | | | 12 g | 9 | 8 (88.9) | | | | | 1 core pass | 8 | 7 (87.5) | | | | | >1 core pass | 1 | 1 (100) | | | | | 14 g or 18 g | 61 | 53 (86.9) | | | | | 1 core pass | 6 | 4 (66.7) | | | | | >1 core pass | 55 | 49 (89.1) | | | | | Number of FNA entries | | | | | | | 1 entry | 60 | | 46 (76.7) | | | | >1 | 10 | | 9 (90) | | | | FNA needle size | | | | | | | 21 g | 53 | | 41 (77.4) | | | | 1 FNA entry | 46 | | 35 (76.1) | | | | >1 FNA entry | 7 | | 6 (85.7) | | | | 25 g | 17 | | 14 (82.4) | | | | 1 FNA entry | 14 | | 11 (78.6) | | | | >1 FNA entry | 3 | | 3 (100) | | | | Hilus | | | | | | | Present | 51 | 44 (86.3) | 36 (70.6) | 15.7% | 12 | | Absent | 19 | 17 (89.5) | 19 (100) | −10.5% | 2 | | Cortex | | | | | | | 2 mm | 1 | 1 (100) | 0 (0) | 100.0% | 1 | | 2.1–4 mm | 13 | 8 (61.5) | 7 (53.8) | 7.7% | 3 | | 4.1–6 mm | 20 | 18 (90) | 15 (75) | 15.0% | 5 | | >6 mm | 36 | 34 (94.4) | 33 (91.7) | 2.8% | 5 | | Shape | | | | | | | Normal | 21 | 16 (76.2) | 11 (52.4) | 23.8% | 5 | | Focal bulge | 20 | 19 (95) | 16 (80) | 15.0% | 5 | | Round | 23 | 22 (95.7) | 22 (95.7) | 0.0% | 2 | | Ill-defined | 6 | 4 (66.7) | 6 (100) | −33.3% | 2 | | Number of suspicious nodes | | | | | | | 1 | 31 | 26 (83.9) | 23 (74.2) | 9.7% | 7 | | 2 | 16 | 13 (81.3) | 11 (68.8) | 12.5% | 4 | | 3 | 10 | 10 (100) | 9 (90) | 10.0% | 1 | | 4 or more | 13 | 12 (92.3) | 12 (92.3) | 0.0% | 2 | | Tumor size by imaging | | | | | | | 5 mm–1 cm | 4 | 4 (100) | 2 (50) | 50.0% | 2 | | >1 cm-2 cm | 19 | 16 (84.2) | 14 (73.7) | 10.5% | 4 | | >2 cm–5 cm | 36 | 31 (86.1) | 31 (86.1) | 2.8% | 5 | | >5 cm | 11 | 9 (81.8) | 8 (72.7) | 9.1% | 3 | | Chemotherapy status | | | | | | | No chemotherapy | 26 | 20 (76.9) | 17 (65.4) | 11.5% | 5 | | Neoadjuvant | 40 | 37 (92.5) | 34 (85.0) | 7.5% | 9 | | Other* | 4 | 4 (100) | 4 (100) | 0.0% | 0 | |
|
|
*Other: 4 patients were both core and FNA positive but did not have axillary surgery.
|